Innerva Pharmaceuticals is a technology company.
Innerva Pharmaceuticals has raised $2.0M across 1 funding round.
Innerva Pharmaceuticals has raised $2.0M in total across 1 funding round.
Innerva Pharmaceuticals has raised $2.0M in total across 1 funding round.
Innerva Pharmaceuticals's investors include Inveready Technology Investment Group.
Innerva Pharmaceuticals is a biotechnology startup developing novel therapies targeting Piezo2 ion channels to treat ocular surface pain and other pain conditions, such as knee joint pain.[1][2] The company focuses on pharmacological blockade of these ion channels in ocular surface nerve endings, with two preclinical assets in development for ocular pain and knee joint pain; it has raised €2.3 million in funding.[1][2]
Innerva serves patients suffering from underserved pain conditions, particularly in ophthalmology, addressing the problem of inadequate treatments for ocular surface pain through innovative neuromodulation approaches.[2][3] As an early-stage firm located at the Parc Científic de Barcelona, it demonstrates growth momentum via secured funding and active preclinical programs, positioning it as a pioneer in Piezo2-targeted pharmaceuticals.[1]
Innerva Pharmaceuticals emerged as a startup from the Parc Científic de Barcelona, specializing in biotechnology therapeutics and diagnostics.[1] While specific founders are not detailed in available sources, the company is led by contact person Patrick Tresserras and is pioneering Piezo2 ion channel-targeted drugs, likely stemming from research into mechanosensitive ion channels for pain management.[1][2]
The idea gained traction through its focus on unmet needs in ocular pain, leading to €2.3 million in funding and advancement of two preclinical assets for ocular and knee joint pain.[1] This early funding and pipeline development mark pivotal moments, humanizing Innerva as a research-driven venture translating scientific breakthroughs into potential therapies.[1][2]
Innerva rides the trend of precision pain management through ion channel modulation, capitalizing on growing interest in mechanosensitive targets like Piezo2 amid rising demand for non-opioid therapies.[1][2] Timing is favorable due to advances in ocular biotech and the push for innovative treatments for chronic pain conditions affecting millions, where current options fall short.[2][3]
Market forces such as increasing ophthalmic startup investments and EU biotech funding support its momentum, while its Barcelona base amplifies access to European research ecosystems.[1] Innerva influences the landscape by validating Piezo2 as a therapeutic target, potentially inspiring similar ventures in neuro-ophthalmology and expanding the startup ecosystem's focus on underserved pain modalities.[1][2]
Innerva is poised for milestone advancements, such as preclinical data readouts or Phase 1 trials for its Piezo2 inhibitors, potentially attracting further venture capital in the competitive biotech funding environment.[1] Trends like AI-driven drug discovery and non-opioid pain innovation will shape its path, enhancing pipeline efficiency and market entry.
Its influence may evolve by establishing Piezo2 blockade as a new standard in ocular and joint pain, tying back to its pioneering role in transforming nerve-ending targeted therapies from concept to clinic.[2]
Innerva Pharmaceuticals has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $2.0M Seed | Inveready Technology Investment Group |